Statement from Ralph G. Neas, President and CEO of the Generic Pharmaceutical Association on Virginia State Biosimilar Law

Published Online: Thursday, March 21, 2013
Follow Pharmacy_Times:
PRESS RELEASE

WASHINGTON, DC (March 21, 2013) — “The law signed today in Virginia (SB 1285/HB 1422) to allow for the substitution of biosimilars in that state, while well intentioned, is pre-emptive, and carries burdensome administrative ‘red tape’ that threatens the positive impact biosimilars will have in Virginia.

No one understands the unique nature of biosimilars better than GPhA, whose members have been manufacturing and providing these complex medicines to patients in Europe for more than eight years. GPhA believes, however, that the time to pass this legislation is after FDA guidance has been issued; and that laws put in place should not create barriers between patients and needed medicines.

FDA Commissioner Margaret Hamburg made the point explicitly in a recent speech, stating ‘The high standards for approval of biosimilar and interchangeable products mean that patients and health care professionals can be assured that when those products go to market, they will meet the standards of safety, efficacy and high quality that everyone expects and counts on. Efforts to undermine trust in these products are worrisome and represent a disservice to patients who could benefit from these lower-cost treatments.’

While GPhA strenuously objects to any bill that includes barriers to biosimilar use that preempts FDA guidance, we welcome the Virginia state legislature’s understanding of the need to limit this legislation by including a two-year ‘sunset’ clause. This clause means that the bill will expire in 2015, likely before an interchangeable biologic is approved and available in the United States. This provision reflects the need to fully understand FDA guidance before instituting long-term regulations affecting biosimilar use.

While the final bill with sunset provisions did pass unanimously, it reflected months of discussion and debate that remains ongoing in other states across the country. GPhA urges state legislators to reject biosimilar substitution legislation that preempts the FDA.”

Related Articles
Today, an expert panel at the 2015 Generic Pharmaceutical Association Annual Meeting, “FDA and Industry Perspectives on Quality Culture,” convened to discuss a shared commitment with industry to the highest standards of manufacturing quality and regulatory processes.
The Generic Pharmaceutical Association today announced the election of its 2015 Executive Committee and Board of Directors.
The Generic Pharmaceutical Association and its members applaud the significant progress made by the agency during Commissioner of Food and Drugs Dr. Margaret Hamburg’s six years leading the U.S. Food and Drug Administration. Throughout her tenure, Dr. Hamburg has been a tireless advocate for patient safety and a leader in efforts to assure that FDA decisions are guided by scientific principles.
The news of Margaret A. Hamburg, MD, resigning from her long-standing post as FDA Commissioner stirred memories of her success with improving access to emergency contraception, but more so her struggles with regulating drug compounding following a deadly fungal meningitis outbreak traced to a compounding pharmacy’s tainted drugs.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$